Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia

Glucagon is a critical regulator of glucose homeostasis; however, mechanisms regulating glucagon action and α-cell function and number are incompletely understood. To elucidate the role of the hepatic glucagon receptor (Gcgr) in glucagon action, we generated mice with hepatocyte-specific deletion of the glucagon receptor. GcgrHep−/− mice exhibited reductions in fasting blood glucose and improvements in insulin sensitivity and glucose tolerance compared with wild-type controls, similar in magnitude to changes observed in Gcgr−/− mice. Despite preservation of islet Gcgr signaling, GcgrHep−/− mice developed hyperglucagonemia and α-cell hyperplasia. To investigate mechanisms by which signaling through the Gcgr regulates α-cell mass, wild-type islets were transplanted into Gcgr−/− or GcgrHep−/− mice. Wild-type islets beneath the renal capsule of Gcgr−/− or GcgrHep−/− mice exhibited an increased rate of α-cell proliferation and expansion of α-cell area, consistent with changes exhibited by endogenous α-cells in Gcgr−/− and GcgrHep−/− pancreata. These results suggest that a circulating factor generated after disruption of hepatic Gcgr signaling can increase α-cell proliferation independent of direct pancreatic input. Identification of novel factors regulating α-cell proliferation and mass may facilitate the generation and expansion of α-cells for transdifferentiation into β-cells and the treatment of diabetes.

[1]  K. Kaestner,et al.  Transcriptional regulation of α‐cell differentiation , 2011, Diabetes, obesity & metabolism.

[2]  R. Kulkarni,et al.  Growth factor signalling in the regulation of α‐cell fate , 2011, Diabetes, obesity & metabolism.

[3]  E. Mema,et al.  Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency. , 2011, Endocrinology.

[4]  J. Treadway,et al.  Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes , 2011, BMC Genomics.

[5]  Zhenguo Liu,et al.  Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival , 2011, Diabetologia.

[6]  D. Drucker,et al.  Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. , 2011, The Journal of clinical investigation.

[7]  J. Egan,et al.  Insulin and Glucagon Regulate Pancreatic α-Cell Proliferation , 2011, PloS one.

[8]  M. Sander,et al.  Historical Perspective: Beginnings of the β-Cell , 2011, Diabetes.

[9]  Katherine A. Winters,et al.  Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. , 2010, American journal of physiology. Endocrinology and metabolism.

[10]  E. Keinan,et al.  Pancreatic β‐Cell Neogenesis by Direct Conversion from Mature α‐Cells , 2010, Stem cells.

[11]  Min Chen,et al.  Pancreas-specific Gsalpha deficiency has divergent effects on pancreatic alpha- and beta-cell proliferation. , 2010, The Journal of endocrinology.

[12]  N. Morgan,et al.  Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes , 2010, Diabetologia.

[13]  G. Warnock,et al.  Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. , 2010, Gastroenterology.

[14]  P. Herrera,et al.  Conversion of Adult Pancreatic α-cells to β-cells After Extreme β-cell Loss , 2010, Nature.

[15]  Katherine A. Winters,et al.  Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[16]  Tanya Hansotia,et al.  Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. , 2009, Gastroenterology.

[17]  Run Yu,et al.  Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, &agr; Cell Hyperplasia, and Islet Cell Tumor , 2009, Pancreas.

[18]  A. Means,et al.  Faculty Opinions recommendation of The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. , 2009 .

[19]  O. Madsen,et al.  The Ectopic Expression of Pax4 in the Mouse Pancreas Converts Progenitor Cells into α and Subsequently β Cells , 2009, Cell.

[20]  P. Gianello,et al.  Native pancreatic α‐cell adaptation in streptozotocin‐induced diabetic primates: importance for pig islet xenotransplantation , 2009, Xenotransplantation.

[21]  T. Asano,et al.  Regulation of Pancreatic β Cell Mass by Neuronal Signals from the Liver , 2008, Science.

[22]  Y. Kido,et al.  Biphasic Response of Pancreatic β-Cell Mass to Ablation of Tuberous Sclerosis Complex 2 in Mice , 2008, Molecular and Cellular Biology.

[23]  Min Chen,et al.  β cell-specific deficiency of the stimulatory G protein α-subunit Gsα leads to reduced β cell mass and insulin-deficient diabetes , 2007, Proceedings of the National Academy of Sciences.

[24]  D. Drucker,et al.  Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice , 2007, Diabetes.

[25]  F. Sundler,et al.  Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet , 2007, Diabetologia.

[26]  J. Gerich,et al.  The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. , 2007, Endocrine reviews.

[27]  Marcela Brissova,et al.  Pancreatic Islet Production of Vascular Endothelial Growth Factor-A Is Essential for Islet Vascularization, Revascularization, and Function , 2006, Diabetes.

[28]  M. J. Charron,et al.  Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. , 2006, Endocrinology.

[29]  O. McGuinness,et al.  Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. , 2006, Diabetes.

[30]  O. Gavrilova,et al.  Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs alpha deficiency. , 2005, The Journal of clinical investigation.

[31]  N. Porksen,et al.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.

[32]  Marcela Brissova,et al.  Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. , 2004, Diabetes.

[33]  Jae-Hyoung Cho,et al.  Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea , 2003 .

[34]  J. Holst,et al.  Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Steiner,et al.  Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice. , 2002, Diabetes.

[36]  K. Kaestner,et al.  Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. , 2001, Genes & development.

[37]  C. Kahn,et al.  Evidence for a circulating islet cell growth factor in insulin-resistant states , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Magnuson,et al.  DNA excision in liver by an albumin‐Cre transgene occurs progressively with age , 2000, Genesis.

[39]  C. Kellendonk,et al.  Hepatocyte‐specific expression of Cre recombinase , 2000, Genesis.

[40]  J. Holst,et al.  Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. , 1995, The Journal of clinical investigation.

[41]  D. Drucker,et al.  Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. , 1994, The American journal of physiology.

[42]  F. Sundler,et al.  Reinnervation of Syngeneic Mouse Pancreatic Islets Transplanted Into Renal Subcapsular Space , 1992, Diabetes.

[43]  R. Unger,et al.  Effects of hypoglycemia and prolonged fasting on insulin and glucagon gene expression. Studies with in situ hybridization. , 1989, The Journal of clinical investigation.

[44]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.

[45]  B. Petersson,et al.  EFFECTS OF LONG TERM ADMINISTRATION OF GLUCAGON ON THE PANCREATIC ISLET TISSUE OF RATS AND GUINEA-PIGS. , 1963, Acta endocrinologica.

[46]  M. Sander,et al.  Historical Perspective: Beginnings of the β-Cell , 2011, Diabetes.

[47]  P. Herrera,et al.  Conversion of adult pancreatic a-cells to b-cells after extreme b-cell loss , 2010 .

[48]  E. Speel,et al.  Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. , 2009, The Journal of clinical endocrinology and metabolism.

[49]  Min Chen,et al.  Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[50]  In Kyu Lee,et al.  Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. , 2003, The Journal of clinical endocrinology and metabolism.